Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00102037 · ClinicalTrials.gov registry record · Phase 2
Use of Activated Recombinant FVII in Spinal Surgery
A Phase 2 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT00102037 is a Phase 2 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 50 participants.
The verdict
NCT00102037, a Phase 2 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
This trial is conducted in the United States of America (USA). The purpose of this clinical research trial is to understand how safe and effective Recombinant Activated FVII is for reducing bleeding and blood transfusions in patients undergoing spinal fusion surgery.
Interventions
- DRUG eptacog alfa (activated)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2004-07 |
| Est. Completion | 2006-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00102037
The ClinicalTrials.gov registry entry for NCT00102037 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which eptacog alfa (activated) is the first listed.
NCT00102037 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00102037 about?
NCT00102037 is a clinical study titled "Use of Activated Recombinant FVII in Spinal Surgery". This trial is conducted in the United States of America (USA). The purpose of this clinical research trial is to understand how safe and effective Recombinant Activated FVII is for reducing bleeding and blood transfusions in patients undergoing spinal fusion surgery.
What is the current status of trial NCT00102037?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2004-07. Estimated completion is 2006-02.
What interventions are being tested in trial NCT00102037?
The interventions under investigation include: eptacog alfa (activated) (DRUG).
Who is sponsoring clinical trial NCT00102037?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.